Breast Cancer gene
BRCA is an abbreviation for Breast Cancer gene. BRCA and BRCA 2 are genes that influence a person’s chances of acquiring breast cancer, and they are present in everybody’s body. Breast Cancer genes are not causes of cancer; rather, they help in fighting breast cancer by repairing breaks in DNA that result in cancer and subsequently the development of tumors. Kuchenbaecker et.al (2017), states that when genes stop functioning properly, they result in gene mutation. Gene mutation means that genes are not able to mend broken DNA, and hence they cannot fight breast cancer. Gene mutation can be inherited from generation to generation. The risk of Breast Gene cancer is that whenever gene mutation occurs, there are high chances that cancer might start developing at an earlier stage. Women are likely to develop cancer of both breasts, and in case women with BRCA and BRCA 2 mutation fail to get breast cancer, the chances are that they might end up developing another cancer in their lifetime.
BRCA and BRCA 2 results in cell growth and cell division. When breast cancer is detected at early stages, it can be treated. The most common types of cancer-related to BRCA and BRCA 2 are ovarian and breast cancer, although gene mutation might expose people to other types of cancer such as prostate cancer which is most common among men. Persons whose family members have suffered from breast or ovarian cancer have high chances of experiencing gene mutation and hence acquiring breast or ovarian cancer. Recommended screenings for mutation include predictive and presymptomatic testing, which are tests carried to identify gene mutations linked with disorders that occur after birth. Predictive testing can detect variations that expose people to genetic disorders. Presymptomatic testing identify the chances of someone developing genetic disorders before signs and symptoms begin to develop (Tung & Garber, 2018). Don't use plagiarised sources.Get your custom essay just from $11/page
References
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., … & Goldgar, D. E. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama, 317(23), 2402-2416.
Tung, N. M., & Garber, J. E. (2018). BRCA 1/2 testing: therapeutic implications for breast cancer management. British journal of cancer, 119(2), 141.